FGFR2 (C491A/V564I)
Sign in to save this workspaceFGFR2 · Variant type: compound · HGVS: p.C491A;p.V564I
Components
p.C491Ap.V564I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Erdafitinib | 99.3% | 0.7% | 95.71 |
| 2 | Selpercatinib | 96.7% | 3.3% | 96.72 |
| 3 | Pemigatinib | 94.5% | 5.5% | 98.23 |
| 4 | Pralsetinib | 91.8% | 8.2% | 93.43 |
| 5 | Deucravacitinib | 86.6% | 13.4% | 98.99 |
| 6 | Pacritinib | 73.0% | 27.0% | 88.64 |
| 7 | Repotrectinib | 70.6% | 29.4% | 84.21 |
| 8 | Entrectinib | 69.0% | 31.0% | 93.69 |
| 9 | Fedratinib | 67.1% | 32.9% | 96.21 |
| 10 | Sunitinib | 65.3% | 34.7% | 91.73 |
| 11 | Infigratinib | 62.5% | 37.5% | 98.24 |
| 12 | Defactinib | 58.1% | 41.9% | 92.68 |
| 13 | Gilteritinib | 56.0% | 44.0% | 88.97 |
| 14 | Tepotinib | 55.6% | 44.4% | 99.75 |
| 15 | Avapritinib | 55.5% | 44.5% | 97.73 |
| 16 | Tivozanib | 54.3% | 45.7% | 92.42 |
| 17 | Tenalisib | 38.2% | 61.8% | 97.98 |
| 18 | Pexidartinib | 33.1% | 66.9% | 99.49 |
| 19 | Alpelisib | 31.6% | 68.4% | 97.22 |
| 20 | Upadacitinib | 30.3% | 69.7% | 97.98 |
| 21 | Sorafenib | 28.9% | 71.1% | 96.72 |
| 22 | Futibatinib | 24.6% | 75.4% | 98.48 |
| 23 | Canertinib | 19.7% | 80.3% | 96.49 |
| 24 | Erlotinib | 18.7% | 81.3% | 99.75 |
| 25 | Darovasertib | 17.1% | 82.9% | 96.99 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Erdafitinib | 99.3% | 99.0% | +0.3% |
| Selpercatinib | 96.7% | 95.0% | +1.7% |
| Pemigatinib | 94.5% | 98.7% | -4.3% |
| Pralsetinib | 91.8% | 93.2% | -1.4% |
| Deucravacitinib | 86.6% | 92.5% | -5.9% |
| Pacritinib | 73.0% | — | — |
| Repotrectinib | 70.6% | 79.8% | -9.2% |
| Entrectinib | 69.0% | 81.5% | -12.6% |
| Fedratinib | 67.1% | — | — |
| Sunitinib | 65.3% | — | — |
| Infigratinib | 62.5% | 98.8% | -36.4% |
| Defactinib | 58.1% | — | — |
| Gilteritinib | 56.0% | — | — |
| Tepotinib | 55.6% | — | — |
| Avapritinib | 55.5% | — | — |
| Tivozanib | 54.3% | — | — |
| Tenalisib | 38.2% | 96.0% | -57.8% |
| Pexidartinib | 33.1% | — | — |
| Alpelisib | 31.6% | 98.9% | -67.3% |
| Upadacitinib | 30.3% | — | — |
| Sorafenib | 28.9% | — | — |
| Futibatinib | 24.6% | 99.3% | -74.7% |
| Canertinib | 19.7% | — | — |
| Erlotinib | 18.7% | — | — |
| Darovasertib | 17.1% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.4ms